Gyre Therapeutics
GYRE
49 hedge funds and large institutions have $75.1M invested in Gyre Therapeutics in 2015 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 10 closing their positions.
3,122% more call options, than puts
Call options by funds: $290K | Put options by funds: $9K
13% more capital invested
Capital invested by funds: $66.2M → $75.1M (+$8.86M)
13% less funds holding
Funds holding: 56 → 49 (-7)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$1.22M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$316K |
| 3 |
Renaissance Technologies
New York
|
+$248K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$221K |
| 5 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
+$37.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$446K |
| 2 |
Two Sigma Investments
New York
|
-$361K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$342K |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$107K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$107K |
GYRE Hedge Fund Activity: Q1 2015 in Review
49 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2015, worth a combined $75.1M — up 13% from $66.2M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GYRE and 3 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $1.22M. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $446K sold.
- 49 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2015, down from 56 in Q4 2014.
- Funds reported $75.1M of Gyre Therapeutics stock for Q1 2015, up 13% quarter-over-quarter.
- 3 funds opened new Gyre Therapeutics positions in Q1 2015 and 10 closed out, a net change of -7 holders.
- The largest Gyre Therapeutics buyer in Q1 2015 was Avoro Capital Advisors, an estimated $1.22M added.
- The largest Gyre Therapeutics seller in Q1 2015 was Two Sigma Advisers, an estimated $446K sold.
Based on aggregated 13F filings for Q1 2015.